Programmable bio-nano-chip systems for serum CA125 quantification: Toward ovarian cancer diagnostics at the point-of-care

Cancer Prevention Research

Volumn 5, Issue 5, 2012, Pages 706-716

  Raamanathan, Archana ^a,c   Simmons, Glennon W ^a   Christodoulides, Nicolaos ^a   Floriano, Pierre N ^a   Furmaga, Wieslaw B ^d   Redding, Spencer W ^e   Lu, Karen H ^b   Bast, Robert C ^b   McDevitt, John T ^a  

^a RICE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAROSE; ANTIBODY; BIOLOGICAL MARKER; CA 125 ANTIGEN; REAGENT;

ANALYTIC METHOD; ARTICLE; BINDING AFFINITY; BIOPROCESS; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER PATIENT; CANCER SCREENING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ANALYSIS; HISTOPATHOLOGY; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MICROFLUIDICS; NANOCHIP; OVARY CANCER; POINT OF CARE TESTING; PRIORITY JOURNAL; PROGRAMMABLE BIONANOCHIP; SENSITIVITY AND SPECIFICITY; SERUM; BIOLOGICAL MODEL; BLOOD; CALIBRATION; CARCINOMA; COMPUTER; EARLY DIAGNOSIS; EVALUATION; HOSPITAL INFORMATION SYSTEM; INSTRUMENTATION; LAB ON A CHIP; METHODOLOGY; MICROCHIP ANALYSIS; OSMOLARITY; OVARY TUMOR; STANDARD; VALIDATION STUDY;

BLOOD CHEMICAL ANALYSIS; CA-125 ANTIGEN; CALIBRATION; CARCINOMA; COMPUTERS; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LAB-ON-A-CHIP DEVICES; MICROCHIP ANALYTICAL PROCEDURES; MODELS, BIOLOGICAL; OSMOLAR CONCENTRATION; OVARIAN NEOPLASMS; POINT-OF-CARE SYSTEMS;

EID: 84866142743     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0508     Document Type: Article

References (47)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Badgwell D, Bast RC Jr. Early detection of ovarian cancer. Dis Markers 2007;23:397-410. (Pubitemid 350171267)
3. Urban N, Drescher C. Potential and limitations in early diagnosis of ovarian cancer. Adv Exp Med Biol 2008;622:3-14.
4. Coticchia CM, Yang J, Moses MA. Ovarian cancer biomarkers: current options and future promise. J Natl Compr Canc Netw 2008;6:795-802.
5. Kohn EC, Azad N, Annunziata C, Dhamoon AS, Whiteley G. Proteomics as a tool for biomarker discovery. Dis Markers 2007;23:411-7. (Pubitemid 350171262)
6. Walsh CS, Karlan BY. Contemporary progress in ovarian cancer screening. Curr Oncol Rep 2007;9:485-93. (Pubitemid 350081485)
7. Urban N. Specific keynote: ovarian cancer risk assessment and the potential for early detection. Gynecol Oncol 2003;88:S75-9; discussion S80-3.
8. van Nagell JR Jr, DePriest PD, Reedy MB, Gallion HH, Ueland FR, Pavlik EJ, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000;77:350-6. (Pubitemid 30368549)
9. Wang Y, Cheon DJ, Lu Z, Cunningham SL, Chen CM, Luo RZ, et al. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. Differentiation 2008;76:1081-92.
10. McLemore MR, Aouizerat B. Introducing the MUC16 gene: implications for prevention and early detection in epithelial ovarian cancer. Biol Res Nurs 2005;6:262-7. (Pubitemid 44289595)
11. Gogoi R, Srinivasan S, Fishman DA. Progress in biomarker discovery for diagnostic testing in epithelial ovarian cancer. Expert Rev Mol Diagn 2006;6:627-37. (Pubitemid 44179947)
12. O'Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol 2001;22:348-66. (Pubitemid 34062947)
13. Karlan BY, McIntosh M. The quest for ovarian cancer's Holy Grail: can CA-125 still be the chalice of early detection? J Clin Oncol 2007;25:1303-4. (Pubitemid 46706873)
14. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-79. (Pubitemid 352777353)
15. Bast RC Jr, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, et al. Early detection of ovarian cancer: promise and reality. Cancer Treat Res 2002;107:61-97.
16. Skates SJ, Xu FJ, Yu YH, Sjovall K, Einhorn N, Chang Y, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995;76:2004-10.
17. Rosenthal AN, Menon U, Jacobs IJ. Screening for ovarian cancer. Clin Obstet Gynecol 2006;49:433-47. (Pubitemid 44181417)
18. Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 2005;23:7919-26. (Pubitemid 46657391)
19. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327-40.
20. Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol 2007;107:526-31. (Pubitemid 350160868)
21. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14:1065-72. (Pubitemid 351302552)
22. Bandera CA, Ye B, Mok SC. New technologies for the identification of markers for early detection of ovarian cancer. Curr Opin Obstet Gynecol 2003;15:51-5. (Pubitemid 36143493)
23. Ye B, Gagnon A, Mok SC. Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. Expert Rev Proteomics 2007;4:121-31. (Pubitemid 46239475)
24. Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST, et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol 2008;199:215-23.
25. Yurkovetsky ZR, Linkov FY, D EM, Lokshin AE. Multiple biomarker panels for early detection of ovarian cancer. Future Oncol 2006;2:733-41. (Pubitemid 44941991)
26. Nosov V, Su F, Amneus M, Birrer M, Robins T, Kotlerman J, et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol 2009;200:639.e1-5.
27. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15 Suppl 3:274-81. (Pubitemid 43096594)
28. Tuxen MK, Soletormos G, Dombernowsky P. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy. Br J Cancer 2001;84:1301-7. (Pubitemid 32522095)
29. Soper SA, Brown K, Ellington A, Frazier B, Garcia-Manero G, Gau V, et al. Point-of-care biosensor systems for cancer diagnostics/prognostics. Biosens Bioelectron 2006;21:1932-42.
30. Rasooly A. Moving biosensors to point-of-care cancer diagnostics. Biosens Bioelectron 2006;21:1847-50.
31. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010;28:2159-66.
32. Whitesides GM. The origins and the future of microfluidics. Nature 2006;442:368-73. (Pubitemid 44264779)
33. Mukhopadhyay R. Microfluidics: on the slope of enlightenment. Anal Chem 2009;81:4169-73.
34. Chin CD, Linder V, Sia SK. Lab-on-a-chip devices for global health: past studies and future opportunities. Lab Chip 2007;7:41-57. (Pubitemid 46016024)
35. Myers FB, Lee LP. Innovations in optical microfluidic technologies for point-of-care diagnostics. Lab Chip 2008;8:2015-31.
36. Jokerst JV, Jacobson JW, Bhagwandin BD, Floriano PN, Christodoulides N, McDevitt JT. Programmable nano-bio-chip sensors: analytical meets clinical. Anal Chem 2010;82:1571-9.
37. Jokerst JV, McDevitt JT. Programmable nano-bio-chips: multifunctional clinical tools for use at the point-of-care. Nanomedicine (Lond) 2010;5:143-55.
38. Jokerst JV, Chou J, Camp JP, Wong J, Lennart A, Pollard AA, et al. Location of biomarkers and reagents within agarose beads of a programmable bio-nano-chip. Small 2011;7:613-24.
39. Nustad K, Bast RC Jr, Brien TJ, Nilsson O, Seguin P, Suresh MR, et al. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol 1996;17:196-219. (Pubitemid 26227618)
40. Scholler N, Crawford M, Sato A, Drescher CW, O'Briant KC, Kiviat N, et al. Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res 2006;12:2117-24.
41. Paek SH, Schramm W. Modeling of immunosensors under nonequilibrium conditions. I. Mathematic modeling of performance characteristics. Anal Biochem 1991;196:319-25.
42. Parsa H, Chin CD, Mongkolwisetwara P, Lee BW, Wang JJ, Sia SK. Effect of volume- and time-based constraints on capture of analytes in microfluidic heterogeneous immunoassays. Lab Chip 2008;8:2062-70.
43. Thompson JA, Bau HH. Microfluidic, bead-based assay: theory and experiments. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:228-36.
44. Zimmermann M, Delamarche E, Wolf M, Hunziker P. Modeling and optimization of high-sensitivity, low-volume microfluidic-based surface immunoassays. Biomed Microdevices 2005;7:99-110. (Pubitemid 40867905)
45. Mongia SK, Rawlins ML, Owen WE, Roberts WL. Performance characteristics of seven automated CA 125 assays. Am J Clin Pathol 2006;125:921-7. (Pubitemid 43801543)
46. Sia SK, Kricka LJ. Microfluidics and point-of-care testing. Lab Chip 2008;8:1982-3.
47. Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res 2011;4:365-74.